EASME

EASME is a European Union executive agency that supports small and medium-sized enterprises and promotes innovation in Europe. It manages projects in the areas of small and medium-sized enterprises, as well as the environment, energy, and maritime sectors, funded by COSME, LIFE, and EMFF. EASME organizes the European Sustainable Energy Week and serves industries such as environmental management, energy production, and maritime activities.

Kristalina Georgieva

Vice President

Past deals in Healthcare

Aenitis Technologies

Grant in 2021
Aenitis Technologies is a French start-up founded in July 2014 by Mauricio Hoyos and Jean-Luc Aider, both researchers associated with the CNRS at the PMMH Laboratory in Paris. The company specializes in the development of medical devices aimed at enhancing cell therapy preparations. By utilizing acoustophoresis technologies, Aenitis Technologies creates innovative solutions for the separation, manipulation, and filtration of biological elements. Their focus is on addressing challenges faced by cell therapy units and blood banks, particularly in areas such as cell sorting, washing, and isolation. Aenitis Technologies aspires to lead the market in filtering and separating solutions through their advanced acoustic preparation techniques, with the ultimate goal of revolutionizing practices in public health.

Orthox

Grant in 2020
Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, focused on developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, which is a significant contributor to osteoarthritis, affecting over 300 million individuals worldwide. The company's flagship product, FibroFix, is a hydrogel biomaterial designed to mimic human knee cartilage, offering solutions for repairing both meniscal and articular cartilage. FibroFix Meniscus and FibroFix Cartilage are specifically tailored to restore function and integrate seamlessly with the body's tissues, promoting rapid recovery and improved mobility. Orthox is preparing to enter clinical trials for its lead product and plans to expand the application of its technology to other joints, as well as explore advancements beyond orthopaedics. With the global biomaterials market projected to exceed $250 billion by 2025, Orthox is well-positioned to capitalize on the growing demand for innovative and effective solutions in joint health.

Vital Beats

Seed Round in 2020
Vital Beats is a developer of a medical platform focused on providing clinical decision support for the remote care of heart patients with pacemakers. The platform employs machine learning and participatory design principles, combined with advanced analytics, to continuously monitor cardiac devices. By utilizing a patent-pending technique, it triages patients effectively, allowing for timely interventions. This approach enhances the management of chronic conditions, ensuring that patients benefit from digital healthcare solutions that monitor their implanted devices around the clock. Vital Beats emphasizes user experience by integrating Nordic aesthetics into its platform, making it both enjoyable and valuable for users.

InterAx Biotech

Grant in 2019
InterAx Biotech Ltd is a biotechnology company based in Villigen, Switzerland, focused on developing a platform for the discovery of functionally selective drugs targeting G-Protein Coupled Receptors (GPCRs). Founded in 2016, the company integrates bioanalytical methods and computational pharmacology to assist in drug candidate design and selection. Its innovative platform combines high-throughput biochemical screening with artificial intelligence and mathematical modeling of cell signaling, facilitating the identification and optimization of drug candidates for various diseases, including those associated with orphan GPCRs. Through its advanced approach, InterAx Biotech aims to improve drug efficacy while reducing side effects, contributing to the healthcare industry's efforts to discover safer and more effective treatments.

Nuada

Grant in 2019
Nuada is a company based in Braga, Portugal, specializing in the development of innovative systems that enhance hand function. Its products are designed to improve performance in healthcare, sports, and various professional activities. Nuada's solutions feature lightweight, breathable, and flexible smart textiles that can be customized to meet individual needs. The technology is non-intrusive and aims to be an essential everyday wearable, providing users with a seamless experience that they may even forget they are wearing.

Hemotune

Grant in 2019
Hemotune AG is a medical device company based in Zürich, Switzerland, founded in 2016. The company specializes in developing a therapeutic blood purification platform aimed at treating various health conditions, particularly infections and blood-related diseases. Utilizing innovative magnetic blood purification technology, Hemotune's device employs magnetic beads to selectively and efficiently remove large biomolecules from the bloodstream. This approach focuses on addressing the immunological aspects of sepsis, enabling the targeted treatment of multiple disease pathways and improving patient outcomes in acute care settings.

Neuro Device Group

Grant in 2019
Neuro Device Group S.A., founded in 2008 and based in Warsaw, Poland, specializes in the development and manufacturing of medical devices aimed at addressing neurological disorders. The company's key products include the Neuro Device Camri, a recording camera for diagnostics within MRI scanners; the Neuro Device Scent, which assesses human neuronal responses to scents; and the Neuro Device Tacti, a stimulator used for identifying brain sensory motor areas during preoperative fMRI diagnostics. In addition to its proprietary devices, the company distributes a range of neurological products from leading manufacturers in various fields, including eye tracking, rehabilitation, and virtual reality. Neuro Device Group is committed to enhancing neurological research and improving health outcomes through innovative technology.

Respinova

Grant in 2019
Respinova specializes in the development of non-invasive devices for the treatment of respiratory disorders, particularly chronic obstructive pulmonary disease (COPD). The company's primary product, the PulseHaler, leverages innovative technology that generates dynamic air pressure pulses. These pulses travel quickly through the airways, creating momentary dilating forces that help open collapsed airways and facilitate mucus clearance. By smoothing and spreading the mucus lining within the airways, the PulseHaler aids in airway clearance and reduces the likelihood of airway re-collapse, providing a significant improvement in treatment options for COPD patients.

Cardiawave

Grant in 2019
Cardiawave, established in late 2014 through a collaboration between the Langevin Institute and the Georges Pompidou European Hospital, specializes in developing non-invasive ultrasonic medical devices aimed at treating heart valve diseases. The company's innovative technology focuses on real-time image guidance to address conditions such as calcified aortic stenosis, minimizing thermal injury and allowing for efficient treatment by clinicians. With a commitment to advancing medical care, Cardiawave has raised over €14 million since its inception to support product development and preclinical studies, paving the way for expected clinical trials to begin. The experienced management team, recognized for its excellence, continues to drive the company's mission to improve patient outcomes in cardiovascular health.

CSF-Dynamics

Grant in 2019
CSF-Dynamics is developing a new type of hydrocephalus shunt that overcomes the major issues of current shunts on the market. The shunt is currently undergoing clinical testing. CSF-Dynamics expects the shunt to be approved for clinical use by end of year 2021.

Mimetis Biomaterials

Grant in 2019
Mimetis Biomaterials SL is a Spanish company founded in 2013, specializing in the design and manufacture of biomimetic bone graft substitutes for medical applications in dental, craniomaxillofacial, and orthopedic sectors. The company focuses on creating synthetic bone grafting solutions that mimic the properties of natural bone, thereby facilitating the colonization of grafts by bone cells and improving outcomes in complex cases. Mimetis offers a range of products, including biomaterial granules and patient-specific 3D-printed grafts, to address various bone defect filling needs. In addition to its product offerings, the company provides consulting, original equipment manufacturing, and co-development services to clinicians. Mimetis Biomaterials was previously known as Subtilis Biomaterials S.L. until its name change in January 2016 and is headquartered in Barcelona, Spain.

Bioithas

Grant in 2019
Bioithas is a biotechnology company dedicated to medical research. Its primary focus is the development of natural treatments that target the root cause of health issues, rather than just symptoms. The company conducts clinical trials in humans to test and validate its personalized treatments, aiming to enhance users' quality of life and overall well-being.

PYRATES

Grant in 2019
PYRATES Established in 2014 and run by Y-generation women, PYRATES smart fabrics provides the solution to protecting their bodies from the polluted, aggressive external elements that surround us through its PYRATEX®: a textile, health-benefitting armour that protects and cares for the wearer’s body.

Radiobotics

Grant in 2019
Radiobotics focuses on developing advanced machine learning algorithms that assist healthcare professionals in the analysis of medical images, particularly x-rays of bones and joints. By automating the reading of these images, the company's technology streamlines routine tasks and enhances access to radiology reports. This innovation aims to improve diagnostic quality, supporting doctors in making informed medical decisions more efficiently.

Surgitate

Grant in 2019
Surgitate specializes in the manufacture of synthetic models aimed at enhancing the training experience for medical and veterinary students, as well as healthcare professionals such as nurses and obstetricians. The company produces a range of models, including synthetic skin, breast, and vascular components, designed to simulate realistic surgical procedures, including incision, dissection, and suturing. This hands-on practice enables users to develop their skills in a controlled environment. Founded by a materials engineer and a thoracic surgeon, Surgitate benefits from the expertise of its investors, Farplas, a leader in plastic automotive parts manufacturing, and Inovent, a pioneer in technology commercialization and seed funding in Turkey. Farplas provides essential support in process development and mass production, while Inovent facilitates connections with potential investors and assists in business and marketing strategies.

Healthplus.ai

Grant in 2019
Healthplus.ai specializes in a surgical patient risk management platform that leverages electronic health record data to enhance surgical care. By utilizing AI and machine learning algorithms, the platform integrates seamlessly with existing EHR workflows to predict potential complications following surgery. This proactive approach allows healthcare professionals to identify early warnings of post-surgery infections and other significant risks, thereby improving patient outcomes and reducing overall costs. Healthplus.ai's technology empowers clinical staff to deliver tailored support to patients, ultimately fostering a more effective and efficient surgical care environment.

D-Tech System

Grant in 2019
D-Tech System is a new generation of disinfection solution providing outstanding performance The D-Tech System is a powerful and ecological disinfection solution, including equipment and environmentally friendly biocidal materials, that eliminates and prevents bacteria growth and has a long lasting disinfection impact. D-Tech caters to demanding industries that require cost effective and modern disinfection procedures in their production facilities and transportation vessels, including food, aquaculture and logistics industries.

Taliaz

Grant in 2019
Taliaz is revolutionizing the treatment and management of mental health disorders with PREDICTIX. PREDICTIX is a CE registered product that provides an advanced decision support software for psychiatrists and general practitioners. Harnessing artificial intelligence (AI), PREDICTIX can enable easy, effective and rapid patient assessment, improved prescribing precision and management for a wide range of mental health conditions. PREDICTIX understands that mental health disorders are multifaceted and unique. Combining data science with machine learning, PREDICTIX translates complex genetic, metabolic, demographic and clinical data into an easy-to-use assessment and prescribing support tool. Starting in the field of depression where the right antidepressant is only prescribed in 49% of cases (Chekroud et al., 2016), PREDICTIX improves treatment prescribing accuracy by 47% to achieve 72% prescribing accuracy*. PREDICTIX PRODUCTS - PREDICTIX Digital – 30% improvement in prescribing accuracy*. Combines AI analysis of patients’ clinical and demographic data to support doctor prescribing decisions. - PREDICTIX Genetics – 47% improvement in prescribing accuracy*. Further optimizes treatment decisions by combining a patient’s DNA analysis with AI. PREDICTIX is an ideal software solution for payors, providers, DNA laboratories and telemedicine providers to improve patient outcomes, reduce costs and expand service offerings in the mental health space. PREDICTIX is commercially available in Europe. Learn more at predictix.ai. *Based on a retrospective analysis of four STAR*D study medications. STAR*D is one of the world’s largest prospective studies for optimal antidepressant administration. Disclaimer: Taliaz is developing the PREDICTIX Genetics and PREDICTIX Digital products. PREDICTIX (Genetics) Antidepressant is currently available for commercial use in the EU and Israel. Outside of the EU and Israel, PREDICTIX Genetics products are currently limited by law for investigational use only. PREDICTIX Digital products are currently limited by law for investigational use only.

Thermetrix

Grant in 2019
Thermetrix Ltd. is a company based in Abercynon, United Kingdom, that specializes in the design and manufacture of hardware and software for personal healthcare systems and devices. Founded in 2016, Thermetrix provides a range of services including design, software development, and research and testing. The company focuses on creating innovative solutions to enhance personal healthcare, reflecting its commitment to improving health management through technology.

TYDOCK PHARMA

Grant in 2019
TYDOCK PHARMA Srl is a knowledge-based biotechnology SME set up in 2006. In 2009, it received an award for being one of the most promising and innovative biotechnology companies in Italy from The Italian Institute for Foreign Trade (I.C.E.). The company is based on integrated drug discovery know-how which relies on 20 years of experience. It is a leading player in the drug discovery field and has seen many collaborations with universities and other biotechnology companies. The Company, as Research and Technology Transfer Centre, is also the recipient of research grants from the European Commission (FP7). TYDOCK PHARMA mainly operates in two business areas: DRUG DISCOVERY PRODUCTS TYDOCK PHARMA focuses on the discovery and early development of chemotherapeutic drugs, with particular emphasis on parasitic diseases (tuberculosis, malaria and protozoarian infections). INNOVATION PROJECT DEVELOPMENT TYDOCK PHARMA is involved in various technology transfer projects aimed at translating innovative technologies from basic research to industrial application.

CreatSens

Grant in 2019
CreatSens develops a platform that provides paper-based creatinine and potassium potentiometric sensors solutions to the healthcare industry. It helps healthcare professionals to better manage the information that can be generated in primary care centers, doctor’s office or patient’s homes. CreatSens platform aims to improve the well-being of people by allowing the monitoring of relevant biochemical parameters of blood out of the lab. The biochemical and physical information will be integrated into a technological platform allowing an accurate prediction, early detection and better prevention of acute conditions from home. The company was founded in 2017 and is headquartered in Tarragona, Catalonia, Spain.

WearHealth

Grant in 2019
WearHealth is a safety and health intelligence solution tailored for organizations involved in heavy-duty and hazardous operations. The company develops an interoperable platform that extracts data from wearable devices to deliver real-time insights into worker safety and health. By utilizing artificial intelligence, WearHealth's platform provides businesses with objective and predictive information, allowing them to proactively identify and mitigate risks before they result in accidents or absenteeism. Unlike traditional health, safety, and wellness tools, WearHealth focuses on providing actionable data that can help detect emergencies and uncover hidden risk factors, thereby enhancing the overall safety of the workforce.

BalanSeat

Grant in 2019
BalanSeat is a medical device developed by MoPair Technologies Ltd., a company founded by a Feldenkrais practitioner with extensive experience in treating neurologically impaired patients, including those with Multiple Sclerosis, Post-Stroke effects, and Parkinson’s disease. The device is designed specifically for the elderly and individuals with neurological impairments, aiming to enhance walking quality, improve balance, and reduce the risk of falls. BalanSeat achieves this by applying rotational movement between the pelvis, trunk, and thighs, which emulates normal walking patterns while the user remains seated. This innovative approach helps older adults regain essential balance and upper-body rotational movement, contributing to their overall mobility and safety.

ChemoTech

Grant in 2019
Scandinavian ChemoTech AB is a clinical development company headquartered in Lund, Sweden. It specializes in cancer care and pain management solutions, primarily through its innovative product, IQWave. This electroporation device uses short electric pulses in conjunction with localized or intravenous chemotherapy to treat various cancers, including head and neck squamous cell carcinoma, malignant melanoma, and breast adenocarcinoma, among others. The company's founders bring extensive experience in surgical oncology and clinical research, driving its commitment to advancing cancer treatment through genuine research and clinical trials. ChemoTech markets its products via distribution channels and a network of opinion leaders across regions such as South East Asia, India, and the Philippines. Established in 2013, the company continues to focus on developing effective therapies for cancer patients.

Lucine

Grant in 2019
Lucine is focused on transforming patient health, primarily in the area of pain management. The company has developed a mobile health application that measures, analyzes, and alleviates pain from the comfort of home. Utilizing advanced algorithms, the application identifies the nature of a patient's pain by analyzing facial expressions, vocal cues, and posture. Based on this real-time assessment, it personalizes treatment options, offering techniques such as exercises, relaxation methods, art therapy, and meditation. The application aims to provide relief within five minutes through innovative analgesic neurostimulation, empowering patients with chronic pain to manage their symptoms effectively.

KronosDNA

Grant in 2019
KronosDNA Srl is a young biomedical company specialized in the reproductive genetics and founded by a team of women, researchers with technical-scientific and managerial expertise. KronosDNA is committed to improving maternal and new born healthcare and facilitating advances in laboratory medicine thanks to the development, prototypization and validation of diagnostic tools to support professionals in the reproductive medicine field.

PlatoScience Medical

Grant in 2019
PlatoScience ApS, founded in 2015 and located in Copenhagen, Denmark, specializes in neurostimulation technology through its product, the PlatoWork headset. This device employs transcranial direct current stimulation (tDCS), a non-invasive method that modulates neuronal activity by applying low-intensity currents to the scalp via electrodes. The technology aims to enhance synaptic plasticity and facilitate a targeted mindset, enabling users to achieve deep focus for various tasks. By making neurostimulation accessible and user-friendly, PlatoScience seeks to support mental health and improve cognitive performance, catering to individuals seeking to optimize their mental capabilities.

300K Solutions

Grant in 2019
300K is a biotechnology start-up composed of a multidisciplinary team with expertise in developing and commercializing innovative life sciences products and services. The company specializes in creating solutions for the storage and shipment of bio-specimens at room temperature. Its stabilization technology enhances the preservation of biological samples, ensuring a secure process while optimizing storage space in life science facilities. By enabling laboratories to stabilize biospecimens at room temperature, 300K aims to minimize sample loss and improve the overall efficiency of biosample management.

Virtual Bodyworks

Grant in 2019
Virtual Bodyworks is a company committed to improving lives by harnessing the power of scientifically-proven breakthrough technology. Their company specialises in immersive virtual reality focused on medical and psychological rehabilitation. Founded by scientists world renowned for their work in VR, we offer products that integrate a unique combination of computer science engineering, neuroscience and psychology.

Kheiron Medical Technologies

Grant in 2019
Kheiron Medical Technologies Limited is a company focused on enhancing breast cancer detection through its innovative product, Mia, an intelligent assessment tool for mammography. Incorporated in 2016 and based in London with additional offices in San Francisco, Budapest, and Amsterdam, Kheiron aims to improve the efficiency, consistency, and accuracy of radiology reporting by integrating advanced deep learning techniques with radiological expertise. The company's mission is to radically enhance outcomes for cancer patients by advancing precision radiology, thereby providing women with better chances in the fight against cancer. Through ongoing research and development, Kheiron strives to transform cancer detection and treatment, marking a significant step forward in the realm of healthcare technology.

TargImmune Therapeutics

Grant in 2019
TargImmune Therapeutics AG is a private Swiss-based biotechnology company focused on drug development using novel targeted onco-immunotherapies. The Company’s principal technology is the CTPIC technology platform that utilizes a non-viral vector to target and destroy cancer cells that over-express certain receptors while simultaneously eliciting an immune response against the cancer cells.

Immundnz

Grant in 2019
Immundnz is an immunology CRO specialised in immune modelling, immune response and tissue damage analysis, in vivo and in vitro cell culture systems for preclinical drug research and development. We are different because we are experienced scientists who will design an experimental model and use customised assays as well as standard assays tailored for the right solution for your problem. We will develop novel assays in our laboratory to meet your specific and unconventional need.

CardiacSense

Grant in 2019
CardiacSense Ltd. is an Israeli company founded in 2012, specializing in the development of medical wearable devices aimed at monitoring heart arrhythmias and other critical health metrics. The company offers FDA and CE certified medical watches and wristbands that provide continuous, long-term, non-invasive monitoring of vital signs, including heart rate, respiratory rate, core temperature, oxygen saturation, and blood pressure. Utilizing advanced photoplethysmography (PPG) technology, CardiacSense's devices enable real-time diagnostics for various medical conditions, including atrial fibrillation, hypertension, chronic obstructive pulmonary disease (COPD), heart failure, sleep apnea, and infections such as COVID-19. By focusing on affordability and comfort, CardiacSense aims to enhance patient care and preventative measures within the healthcare industry.

Cogvis

Grant in 2019
CogvisAI is a human behavior analytics platform focused on enhancing caregiver support in healthcare settings. Founded in 2007 as a spin-off from TU Wien, the company specializes in computer vision, machine learning, and 3D data analytics. Its technology aims to improve productivity in nursing homes by up to 30% while significantly reducing the risk of fall-related incidents by over 70%. The platform operates on a privacy-protecting patient monitoring system that utilizes a 3D infrared sensor to track mobility and care intensity trends. This system provides actionable insights for effective workflows and care intervention planning, enabling nursing professionals to deliver high-quality, patient-centric care. CogvisAI's applications extend to elderly care, cognitive impairment support, psychosocial institutions, oncology departments, and rehabilitation centers, with potential developments in occupational health, robotics, and physical therapy.

Gedea Biotech

Grant in 2019
Gedea Biotech AB, founded in 2015 and based in Lund, Sweden, focuses on developing an antibiotic-free treatment for vaginal fungal infections, a common issue affecting approximately 75% of women at some point in their lives. The company's key product, GA101, utilizes natural substances to lower vaginal pH, provide physical barrier protection, and inhibit biofilm formation. This innovative approach aims to offer a safe and effective solution for treating and preventing vaginal infections without the use of antibiotics. Gedea Biotech is committed to addressing women's health needs through its unique treatment options.

TransCure BioServices

Grant in 2019
TransCure bioServices SAS, founded in 2012 and located in Archamps, France, specializes in vivo pharmacology preclinical services tailored for pharmaceutical, biotech, start-up, and academic researchers. The company offers unique research and development platforms, including the Humanized Immune System (HIS) and Human Immunodeficiency Virus (HIV) mouse models. These platforms are accessible as fee-for-service solutions, enabling clients to profile new drugs targeting immuno-related diseases and develop novel anti-HIV/AIDS therapies. By providing humanized mouse models that better predict human drug responses compared to traditional models, TransCure bioServices helps accelerate the development and commercialization of new drugs and therapies, facilitating a more efficient pathway for researchers to bring innovative treatments to market.

Astraveus

Grant in 2019
Astraveus is transforming cell and gene therapy (CGT) manufacturing through its Lakhesys™ platform, an innovative cell foundry that leverages deep process optimization and microfluidic bioprocessors. This technology allows for the production of personalized biological therapies with minimal infrastructure requirements, ultimately reducing costs and addressing logistical challenges in the industry. By automating autologous bioproduction, the platform enhances the efficiency of transforming cells into therapeutic agents, enabling healthcare providers to scale the development and manufacturing of CGT solutions. Astraveus aims to improve patient access to these vital therapies while minimizing environmental impact.

Picterus

Grant in 2019
Picterus is developing a smartphone application aimed at diagnosing jaundice in newborns, a condition that contributes to over 100,000 deaths annually, particularly in impoverished areas of Sub-Saharan Africa and South Asia. Existing screening devices are prohibitively expensive, often costing around $7,000, which limits access in low-resource settings. The app utilizes patented biomedical optics technology to provide accurate estimates of jaundice levels while accounting for variations in skin pigmentation. This innovation addresses the growing need for affordable and effective diagnostic tools, especially given the trend of shorter hospital stays post-birth and the rising rates of jaundice-related hospital readmissions. By enabling parents to monitor their child's jaundice levels at home, Picterus aims to improve health outcomes for vulnerable populations.

Arteries Studio

Grant in 2019
Arteries Studio Kft. is a Budapest-based firm established in 2003 that specializes in the development of web and mobile applications for businesses in Hungary. The company's web development services encompass the creation of websites, webshops, online software, and Odoo ERP systems. In mobile application development, Arteries Studio focuses on platforms such as iOS, Android, and wearable devices, including smartwatches and Google Glass. Additionally, the company offers graphic design services, which include corporate identity, desktop publishing design, and 3D modeling. Arteries Studio also provides storage and hosting solutions, along with online invoice payment services. Over the years, the studio has collaborated with notable clients, including Unilever, KPMG, NATO, and Bosch, and has increasingly concentrated on creating business applications and health-related web solutions, often integrating external hardware and smart sensors in partnership with manufacturers.

Chemicare

Grant in 2019
Chemicare is a biotechnology company established in December 2016, focused on the discovery and development of orphan drugs for patients with calcium-related genetic diseases. The company aims to improve the quality of life for individuals suffering from conditions such as Tubular Aggregate Myopathy, York Platelet Syndrome, and Stormorken Syndrome. Chemicare is dedicated to creating therapies that address the abnormal intracellular calcium levels characteristic of these rare diseases, enabling healthcare professionals to provide effective treatment options for affected patients.

Hystrix Medical

Grant in 2019
Hystrix Medical operates a digital marketplace that connects healthcare organizations with suppliers of medical devices and consumable products. This platform streamlines the procurement process, significantly reducing the time required for purchasing from the typical 4-6 months to a more efficient system. By providing a transparent market price landscape and facilitating one-stop contracting, Hystrix Medical enhances the efficiency of hospital procurement personnel and suppliers. The platform focuses on products that require minimal explanation, allowing for straightforward transactions. Users have reported average total cost savings of 40%, highlighting the platform's effectiveness in optimizing purchasing processes and fostering better trade relationships in the healthcare sector.

Biel Glasses

Grant in 2019
Biel Glasses, SL, founded in 2017 and based in Barcelona, Spain, specializes in the development and sale of electronic smart glasses aimed at enhancing mobility and personal autonomy for individuals with low vision. The company’s innovative glasses utilize 3D vision and artificial intelligence algorithms to detect obstacles and environmental changes, translating this information into a format that users can perceive with their remaining vision. Additionally, the glasses feature zoom and image enhancement capabilities, providing a comprehensive solution to support users in navigating their daily lives safely and independently.

Yetitablet

Grant in 2019
Yetitablet is the most intuitive, versatile and high-performance giant tablet. What makes it special is its open Android OS, a high-performance hardware and curated applications for different industries like healthcare, education, construction, business and tourism. With the Yetitablet they enable their customers to learn, play, communicate and collaborate more efficiently. For more info, visit www.yetitablet.com

ImmuneBiotech

Grant in 2019
ImmuneBiotech AB, founded in 2013 and based in Lund, Sweden, specializes in the research and development of innovative microbiome therapeutics. The company focuses on creating novel probiotics derived from lactic acid bacteria and synbiotic formulations that aim to influence gut microbiota and immune system responses. ImmuneBiotech's therapeutic products include combinations of probiotics, prebiotics, and proteins, specifically designed to address various inflammatory disorders such as multiple sclerosis, rheumatoid arthritis, and type 1 diabetes. By leveraging its online platform, the company seeks to enable healthcare professionals to prevent and treat autoimmune and other chronic inflammatory conditions effectively.

ABLE Human Motion

Grant in 2019
ABLE Human Motion is a Barcelona-based medical device start-up founded in 2018 that specializes in the development of robotic exoskeletons designed to improve mobility for individuals with disabilities. The company's primary product, the ABLE Exoskeleton, is a lightweight and user-friendly wearable device that assists paraplegic users in standing, walking, and sitting. This innovative technology employs a motor and gearbox to mimic muscle movement, along with an inertial sensor to interpret the user's intentions. ABLE Human Motion aims to enhance the quality of life for wheelchair users by promoting greater independence and mobility while also providing rehabilitation tools for clinicians to improve treatment efficiency.

Elypta

Grant in 2019
Elypta AB is a molecular diagnostic company based in Stockholm, Sweden, specializing in the development of a metabolism-based liquid biopsy platform aimed at the early detection and monitoring of cancer. Founded in 2017, the company focuses on measuring biomarkers in blood and urine, employing machine learning and artificial intelligence algorithms to identify cancer signatures. Elypta is actively conducting the AURORAX clinical trial series to explore applications for its platform, particularly in renal cell carcinoma, while also investigating other cancer indications. The technology includes a new in vitro diagnostic laboratory assay kit, which enables comprehensive profiling of glycosaminoglycan metabolites and supports a range of applications from screening to treatment response monitoring, facilitating earlier interventions in cancer care.

Inflection Biosciences

Grant in 2019
Inflection Biosciences Ltd. is a drug development company focused on discovering and developing small molecule therapeutics for cancer treatment. Founded in 2012 and based in Dublin, Ireland, with additional operations in London, the company aims to identify promising early-stage cancer research from academic institutions and other organizations globally. Its research pipeline includes innovative PIM kinase inhibitors and multi-targeting kinase inhibitors that are currently in preclinical development. With a team that combines over 60 years of industry experience, Inflection Biosciences is dedicated to advancing its most promising programs through early clinical stages, with plans to partner with larger pharmaceutical companies for later-stage development and commercialization. The company also explores therapeutics for autoimmune and inflammatory diseases, solid tumors, and hematological malignancies, striving to enhance treatment options for healthcare providers.

Yakna

Grant in 2019
Yakna develops neurorehabilitation applications and hardware professional education popularization of science.

SagaNatura

Grant in 2019
SagaNatura is an Icelandic biotech company that specializes in the development, production, and export of health products derived from premium Icelandic ingredients. The company focuses on the organic herb Archangelica Angelica and high-quality Astaxanthin, offering a range of consumer products that are safe, vegan-friendly, and of Icelandic origin. SagaNatura operates under two primary brands, SagaMedica, established in 2000, and KeyNatura, launched in 2014. The company aims to promote healthier lifestyles through its clean-label nutrition products, which address various health issues, including vision, skin health, energy, and concentration. By leveraging Iceland's pristine environment, SagaNatura is committed to providing high-quality health solutions that contribute to the well-being of consumers.

Aspivix

Grant in 2019
Aspivix SA is a Swiss company specializing in the development of innovative medical devices aimed at enhancing gynecological procedures. Founded in 2015 and headquartered in Lausanne, Aspivix focuses on creating minimally invasive surgical instruments that prioritize patient comfort and safety. Its flagship product, CAREVIX, utilizes a patented suction technology to stabilize the cervix during procedures, effectively reducing pain and minimizing the risk of bleeding, lesions, and infections. This approach replaces traditional methods, such as the use of forceps, offering a gentler alternative for both women and gynecologists. Through its advancements, Aspivix aims to transform the landscape of gynecological care by making procedures safer and more efficient.

Nateo Healthcare

Grant in 2019
Nateo Healthcare, founded in 2016 and based in Toulouse, France, specializes in designing, developing, and manufacturing medical devices for the fields of gynecology and obstetrics. The company focuses on creating innovative connected medical devices and software that enable healthcare professionals to monitor the health of expectant mothers and their unborn babies. Among its key products is a belt equipped with ultrasound probes that can assess fetal positions, measure the mother's heart rate, and monitor uterine contractions. Additionally, Nateo Healthcare is working on a new generation of mobile and connected fetal heart rate monitors, which facilitate both hospital and home fetal telemonitoring, allowing for enhanced patient self-monitoring and tailored healthcare interventions.

liberDi

Grant in 2019
liberDi is an Israeli company that specializes in portable automatic peritoneal dialysis systems designed for patients with end-stage renal disease. The company offers an innovative all-in-one Digital Dialysis Clinic that enables patients to manage their own dialysis with the help of an Intelligent Dialysis Assistant and remote medical supervision. This system allows patients to perform peritoneal dialysis from various locations, including their homes, offices, or while traveling, thereby enhancing their quality of life and reducing reliance on traditional in-clinic care. Founded in 2014 by a team of experts in science and medicine, liberDi aims to free dialysis patients from the constraints of frequent visits to expensive clinics. Its technology not only empowers patients but also helps clinics optimize their operations and reduce costs, creating a comprehensive platform for renal care that benefits both patients and healthcare providers.

Stemcis

Grant in 2019
Stemcis is a medical device manufacturer based in Saint-Denis, France, focused on the research and development of adipose tissue. The company specializes in creating surgical kits designed for the collection, treatment, and re-injection of fat cell preparations. Their work in tissue engineering encompasses both human and veterinary medicine, addressing various pathologies through innovative protocols and medical solutions. Through its commitment to advancing adipose tissue applications, Stemcis aims to enhance treatment options in the medical field.

Mimetas

Grant in 2019
MIMETAS B.V., founded in 2013 and based in Leiden, the Netherlands, specializes in the development of microfluidics-based culture plates designed for the cultivation and screening of three-dimensional organ and tissue models. The company's product line includes OrganoPlate 2-lane and 3-lane systems, which facilitate early-stage screening for drug efficacy and toxic side effects. By addressing the discrepancies between traditional in vitro and animal models and actual patient responses, MIMETAS aims to enhance the predictability of drug testing. Its OrganoPlates enable high-throughput screening of customized disease, toxicology, and transport models, thereby providing researchers and clinicians with innovative tools for compound testing and fundamental research.

OnDosis

Grant in 2019
OnDosis is a company focused on transforming medication delivery through its proprietary technology, which allows for flexible and individualized dosing of oral medicines formulated as micro units. The company aims to enhance disease management, support patient adherence, and improve convenience for individuals with conditions such as ADHD, pain management, and organ transplant immunosuppression. By offering improved dosing options, OnDosis seeks to address significant healthcare burdens and ultimately enhance patient outcomes. Founded in 2017 and headquartered in Gothenburg, Sweden, OnDosis emerged from research initiated at AstraZeneca and is supported by strategic partnerships in formulation, device development, regulatory affairs, and business development. The company's innovative dosage manager integrates digital technologies with conventional drug treatments, positioning it to make a meaningful impact in personalized medicine.

OmniSpirant

Grant in 2019
OmniSpirant develops regenerative gene therapies with the potential to transform respiratory medicine.

Natac

Grant in 2019
Natac specializes in the research, development, and sustainable manufacturing of plant extracts and natural origin ingredients. The company serves various sectors, including nutraceuticals, pharmaceuticals, food, animal nutrition, and cosmetics, by providing access to high-quality bioactive compounds. Committed to exceeding industry standards, Natac employs a proprietary analytical method, HABOID, to ensure the purity of its botanical products. Sustainability is a core principle of Natac's operations, as it systematically evaluates agricultural processes to identify areas for improvement and investment. By utilizing the whole plant, the company aims to minimize the environmental impact of its production methods. Natac is strategically located in Spain, where it houses its manufacturing, research and development, and quality assurance departments, ensuring adherence to European standards while also maintaining a presence in international markets.

Regentis Biomaterials

Grant in 2019
Regentis Biomaterials Ltd. is a tissue repair company specializing in the development and commercialization of biodegradable hydrogels aimed at regenerating damaged cartilage tissue. The company's primary product, GelrinC, is a hydrogel designed for the treatment of articular cartilage lesions and is currently undergoing clinical trials. GelrinC serves a range of orthopedic applications, including microfracture and autologous chondrocyte implantation procedures. The hydrogel platform, Gelrin, combines polyethylene glycol diacrylate and denatured fibrinogen, offering both the stability of synthetic materials and the bio-functionality of natural substances. Founded in 2004, Regentis Biomaterials is headquartered in Or-Akiva, Israel, with an additional office in Princeton, New Jersey. The company is committed to enhancing patient health and quality of life through innovative tissue repair solutions.

Biom'Up

Grant in 2019
Biom'Up S.A. is a French company based in Saint-Priest that specializes in the development and commercialization of hemostatic products utilizing patented biopolymers and collagen technology. Established in 2005, Biom'Up designs, manufactures, and sells innovative medical devices that enhance surgical practices across various specialties, including orthopedic, spinal, cardiac, general, maxillofacial, and laparoscopic surgeries. Their flagship products, HEMOBLAST bellows and associated laparoscopic applicators, aim to simplify surgical procedures and improve patient outcomes by facilitating guided regeneration of soft tissues and bone. The company markets its offerings primarily in Europe and the United States.

Orthox

Grant in 2019
Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, focused on developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, which is a significant contributor to osteoarthritis, affecting over 300 million individuals worldwide. The company's flagship product, FibroFix, is a hydrogel biomaterial designed to mimic human knee cartilage, offering solutions for repairing both meniscal and articular cartilage. FibroFix Meniscus and FibroFix Cartilage are specifically tailored to restore function and integrate seamlessly with the body's tissues, promoting rapid recovery and improved mobility. Orthox is preparing to enter clinical trials for its lead product and plans to expand the application of its technology to other joints, as well as explore advancements beyond orthopaedics. With the global biomaterials market projected to exceed $250 billion by 2025, Orthox is well-positioned to capitalize on the growing demand for innovative and effective solutions in joint health.

Stokhos Emergency Mathematics

Grant in 2019
Stokhos B.V., based in Amsterdam, Netherlands, develops software aimed at optimizing the deployment of emergency vehicles, particularly ambulances. Initially conceived as a scientific mathematical project named REPRO, the company's flagship product, known as seconds, utilizes advanced algorithms to provide real-time coverage advice to emergency dispatch centers. By analyzing factors such as population density, historical incident data, and road networks, Stokhos's platform enables dispatchers to determine the optimal placement of ambulances, ensuring that they can respond swiftly to emergencies within required timeframes. The team at Stokhos is deeply committed to enhancing public safety and has a strong connection to the medical emergency sector, with all members holding valid first aid certifications.

Saphenus Medical Technology

Grant in 2019
Saphenus has decoded phantom pain and enlarge gait stability through the sense of touch idea and the findings of the medicine nobel price 2021. Globally, millions of amputees face the devastating challenge of phantom pain, with no effective solution available until now. This constant, debilitating pain significantly impacts their quality of life. Saphenus has developed a groundbreaking technology that not only decodes phantom pain but also enhances mobility and stability through an innovative sensory feedback system, redefining what prosthetics can achieve. The urgency of our approach is underscored by the ongoing crisis in conflict zones like Ukraine-Russia and Israel-Palestina. These individuals urgently need faster, pain-free, and effective prosthetic solutions. With the establishment of our partnership with Ternopil Medical University in 2024, Saphenus is uniquely positioned to bring its innovation to those who need it most, offering renewed hope and quality of life. https://www.ukrinform.ua/rubric-regions/3916291-u-ternopoli-vijskovi-otrimali-innovacijni-priladi-do-proteziv-vid-avstrijskoi-kompanii.html Our technology is not just a medical breakthrough but a humanitarian imperative, poised to transform the lives of millions worldwide. Saphenus was awarded 2024 from the European Institute of Technology as one of the 6 best medtech startups in Europe.

Evidence-Based Behavior

Grant in 2019
Evidence-Based Behavior (eB2) is a company that develops healthcare solutions for psychiatric patients using Artificial Intelligence and mobile technologies.

Brain Stimulation

Grant in 2019
Brain Stimulation AB is a Swedish small and medium-sized enterprise established in 2011, focusing on the assessment and rehabilitation of patients recovering from strokes and traumatic brain injuries. The company utilizes advancements in brain plasticity research to offer innovative rehabilitation solutions, particularly for cognitive impairments and attention disabilities, such as Spatial Neglect. By addressing the global need for effective rehabilitation in conditions like stroke, dementia, traumatic brain injuries, and Parkinson's disease, Brain Stimulation employs a concept known as Enriched Rehabilitation. Their approach combines precision diagnostics with individualized care technology, facilitating effective neurological rehabilitation that can be accessed remotely. This method aims to create a motivating rehabilitation environment that leads to proven and lasting improvements in patients' cognitive and motor functions, ultimately enhancing their recovery process.

Nasal

Grant in 2019
Nasal is a technology-focused company that specializes in developing automated medical devices for the healthcare sector. It aims to enhance professional practices by providing tools that offer detailed insights into the structure and behavior of the nasal cavity. Through its innovative solutions, Nasal seeks to advance medical simulation technology, thereby assisting and training healthcare professionals. The company's efforts are geared towards improving the quality of care for patients and supporting the ongoing development of medical expertise.

Double Bond Pharmaceutical

Grant in 2019
Double Bond Pharmaceutical is a pharmaceutical company focused on developing and commercializing innovative treatments for cancers, infections, autoimmune diseases, and other life-threatening conditions. The company aims to address unmet medical needs by providing more efficient and safer therapeutic options for patients. Through its first-in-class approaches, Double Bond Pharmaceutical seeks to improve patient outcomes and contribute significantly to the healthcare market.

Amypore

Grant in 2019
Amypore is focused on developing innovative therapies for Alzheimer's and Parkinson's diseases through its lead product, AmyP53. This chimeric peptide is created using an advanced artificial intelligence strategy applied to molecular neuroscience. AmyP53 targets a common mechanism in both neurodegenerative diseases by blocking the formation of neurotoxic structures, specifically oligomers of amyloid proteins, which are implicated in disease progression. As the first representative of a new therapeutic class, AmyP53 offers a unique approach to treatment, aiming to provide patients with effective solutions for conditions that currently lack adequate therapies.

EarWays Medical

Grant in 2019
EarWays Medical Ltd. is an innovative company focused on developing ear-care solutions aimed at improving the well-being of children and adults globally. The company specializes in a medical device designed for the effective removal of earwax, utilizing a patented technology that features a flexible, coated helical tip for easy navigation in the ear canal. This device is suitable for both clinicians and home users, facilitating the management and extraction of cerumen. Backed by a team of experts in bioengineering, medical devices, and ear health, EarWays Medical is well-positioned to address the medical demand for accessible and effective ear care, helping to prevent temporary hearing loss caused by earwax buildup.

PlumeSTARS

Grant in 2019
PlumeSTARS is a specialized pharmaceutical company focused on drug delivery systems for the treatment of respiratory diseases. The company develops antibiotics specifically designed to address lung infections in patients with Cystic Fibrosis. By discovering novel orphan medicines and utilizing advanced technologies for various active pharmaceutical ingredients (APIs), PlumeSTARS aims to create innovative inhalation therapies that improve patient outcomes. Their commitment to developing effective treatments positions them as a significant player in the field of respiratory health.

Mecwins

Grant in 2019
Mecwins specializes in developing advanced nanomechanical sensing technology to create sensitive immunoassays aimed at improving healthcare outcomes for individuals at risk for oncology, cardiovascular diseases, and infectious diseases. Their innovative platform combines nanomechanical sensing with plasmonic emission using a sandwich immunoassay approach, allowing for the production of ultrasensitive detection systems. This technology enables researchers to achieve enhanced sensitivity in disease detection, ultimately contributing to better diagnostics and treatment options in critical areas of healthcare.

Vulcur Medtech

Grant in 2019
Vulcur Medtech is a medical device development company based in Vanløse, Denmark, established in 2018. The company specializes in wound healing through its innovative VMT laser technology, which targets chronic wounds that are otherwise difficult to treat. This advanced device utilizes laser pulses that effectively eliminate biofilm-producing bacteria while preserving healthy human cells, promoting the body's natural healing process. By significantly reducing healing time, Vulcur Medtech enhances the quality of life for patients suffering from chronic wounds.

Diapath S.p.A

Grant in 2019
Diapath S.p.A. is a privately held company that specializes in the anatomic pathology sector, providing a range of high-quality products and customized services to hospitals and laboratories globally. The company manufactures reagents, medical instruments, and consumables designed for modern anatomical and cytology laboratories. Its product lineup includes high-tech instruments, stains, tissue processing dyes, and microtomy supplies, all developed to meet rigorous quality standards. With a commitment to innovation and reliability, Diapath aims to establish itself as a leading brand in anatomic pathology, emphasizing customer needs and delivering tailored solutions.

Algalif

Grant in 2019
Algalif supplies astaxanthin products from microalgae, including ingredients and finished formulations. They help solve the nutritional needs of current and future generations through the development and delivery of sustainable microalgae ingredients. They also commercialize a range of immune-health ingredients, for use in food, beverages, nutraceuticals, sports nutrition, and personal care products.

ZygoFix

Seed Round in 2019
ZygoFix is a medical device company focused on spine technology. It has developed a three-dimensional printed implant designed to lock the facet joint of the lumbar spine. This innovative device leverages the anatomy of the spine to provide stability, moving away from traditional external screw-based systems. By eliminating the need for pedicle screws, ZygoFix aims to reduce the risks associated with improper screw placement, enhancing patient safety and outcomes in spinal surgeries.

Pila Pharma

Grant in 2019
Pila Pharma AB is a clinical stage biotech company based in Malmö, Sweden, focused on developing XEN-D0501, a potent and selective TRPV1 antagonist. This innovative compound is being investigated as a treatment for type 2 diabetes, obesity, and the rare painful condition known as erythromelalgia. XEN-D0501 has undergone testing in over 300 subjects during phase 1 and phase 2 trials, demonstrating a favorable safety profile in healthy volunteers and patients with various conditions, including overactive bladder disease and chronic cough. The compound has shown efficacy in improving glucose-stimulated insulin secretion in type 2 diabetics. Recent preclinical studies have completed successfully without any registered side effects, allowing XEN-D0501 to advance to longer clinical trials. In July 2022, Pila Pharma received US Orphan Drug Designation for this compound in the context of erythromelalgia.

ODI Medical

Grant in 2019
ODI Medical specializes in developing innovative technology for the bedside evaluation of circulatory failure through the assessment of microcirculation. The company's medical device streamlines the collection of microvascular data and has diverse clinical applications. These include monitoring patients on mechanical heart and lung machines, evaluating the toxicity of chemotherapy, and early detection of evolving sepsis. Additionally, the technology is useful for monitoring chronic wounds and conducting mass screenings for conditions such as Ebola, bird flu, and epidemic meningitis. By employing non-invasive techniques, ODI Medical enables healthcare professionals to enhance patient therapy through improved assessment of microcirculation.

Deneb

Grant in 2019
Deneb Medical is a start-up focused on creating a robotic platform intended for various surgical applications, including neurosurgery, cranio-maxillofacial surgery, head and neck surgery, urology, and general surgery. The company's technology centers around a laser-based robotic surgery system that assists surgeons, particularly in spine surgery, by utilizing optical and photonic techniques for tissue ablation. This innovative system enhances surgical precision and efficiency through features such as three-dimensional visualization and augmented reality guidance, ultimately aiming to facilitate minimally invasive procedures and improve patient outcomes.

HEPHAISTOS-Pharma

Grant in 2019
Hephaistos Pharma is a biotechnology company focused on advancing oncology treatments through innovative immunotherapy solutions. The firm develops a platform that utilizes active and non-specific immuno-stimulants to enhance the effectiveness of existing antibodies by transforming cold tumors into hot targets, which can significantly improve patient outcomes. This approach aims to address unmet medical needs in cancer treatment, enabling patients to tackle previously incurable cancers. Hephaistos Pharma is dedicated to elevating immunotherapy efficiency by stimulating immune responses, thereby offering new hope in the fight against cancer. Interested parties can access more information through an online inquiry form available on the company's website.

VisionHealth

Grant in 2019
VisionHealth GmbH is a healthcare technology company based in Munich, Germany, founded in 2017. It specializes in creating software solutions for patients with various respiratory diseases, particularly those reliant on inhalers for conditions such as asthma and COPD. Its primary product, Kata, is a digital healthcare assistant that utilizes artificial intelligence and machine learning to improve inhalation therapy. The application facilitates effective inhaler use by providing training and support, helping patients avoid shortness of breath and reduce the need for hospital visits. By enhancing the management of chronic lung conditions, VisionHealth aims to lower therapy costs and improve the overall quality of life for patients.

Allergy Data Laboratories

Grant in 2019
Allergy Data Laboratories continues to manage and support the Allergome project.

Cytox

Grant in 2019
Cytox Limited specializes in developing products and services aimed at diagnosing and treating neurodegenerative disorders, particularly Alzheimer's disease. The company has created a genetic-based blood test that assesses the risk and diagnosis of Alzheimer's in its early stages, addressing a critical need as the prevalence of the disease rises globally. Cytox's offerings include cellular and genetic assays for identifying cell cycle deficits in patients, along with biomarker and drug-screening services for pharmaceutical companies engaged in clinical trials. The company collaborates with Affymetrix, part of Thermo Fisher Scientific, to enhance its commercial testing capabilities. Founded in 2004 and headquartered in Birmingham, United Kingdom, with additional offices in Manchester and Oxford, Cytox serves pharmaceutical and biotechnology firms, as well as research laboratories involved in clinical research and drug development.

VSPARTICLE

Grant in 2019
VSPARTICLE is a company that specializes in the development of nanoparticle generators for a wide range of applications, including sensors, batteries, catalysis, solar cells, healthcare, and additive manufacturing. Founded in 2014 and headquartered in Delft, The Netherlands, VSPARTICLE's technology allows for the on-site production of nanoparticles, facilitating their immediate integration into final products. This capability supports researchers and industries in creating sustainable materials and innovative applications by providing essential building blocks for various sectors. By streamlining the production process, VSPARTICLE enables faster development cycles and promotes the advancement of new technologies.

Cellestia

Grant in 2019
Cellestia Biotech AG is a clinical-stage biopharmaceutical company specializing in the development of innovative therapies for cancer and immunological disorders. Founded in 2014 as a spin-off from the École Polytechnique Fédérale de Lausanne, the company is headquartered in Basel, Switzerland, with an additional location in Lausanne. Cellestia focuses on its lead compound, CB-103, which is a novel oral pan-NOTCH inhibitor targeting NOTCH-dependent leukemia, lymphoma, and solid tumors. The drug has successfully advanced to Phase 2 clinical trials for patients with multi-drug resistant cancers. In addition to CB-103, Cellestia is developing a pipeline of novel transcription factor inhibitors and NOTCH-specific biomarkers to enhance patient selection and treatment outcomes. The company's approach aims to control and modulate pathogenic gene expression through selective inhibition of transcription factors in the cell nucleus, contributing to integrated drug and personalized medicine development.

Limbic

Grant in 2019
Limbic is a London-based company that specializes in mental healthcare technology. Founded in 2017, it develops a software development kit (SDK) that leverages machine learning to analyze heart rate data collected from wearable devices like the Apple Watch, allowing for the assessment of users' emotional states. Limbic also offers psychological therapies for adults, focusing on improving mental health through innovative solutions. Its platform supports healthcare professionals by providing tools for stress detection and facilitating clinical assessments, thereby enhancing the efficacy of psychological therapy. By combining AI technology with wearable devices, Limbic aims to address the growing challenges in mental health care and improve patient outcomes.

Somax Systems

Grant in 2019
Somax Systems specializes in the development and commercialization of high-performance ultrasound imaging devices tailored for the healthcare sector. The company is on the verge of launching a pocket-sized scanner that is expected to become an essential tool for health professionals, akin to the stethoscope or thermometer. This innovative device offers high-resolution imaging with real-time zoom capabilities and allows for wireless data transmission via Wi-Fi, enhancing the efficiency of healthcare providers. Somax Systems is committed to delivering superior quality products that meet the needs of users and provide sustainable value, grounded in principles of trust, innovation, creativity, and entrepreneurship.

Pregnolia

Grant in 2019
Pregnolia AG, established in 2015 and headquartered in Zurich, Switzerland, specializes in the development of a diagnostic device that predicts the risk of premature birth during pregnancy. The company's core product is a medical probe that measures the strength of the uterine cervix, enabling early intervention to prolong gestation and enhance neonatal health outcomes. Pregnolia serves pregnant women and gynecologists, aiming to ensure every woman experiences a happy, healthy, and informed pregnancy. The company's dedicated team, including Sabrina, Francisco, and Annette, is committed to completing clinical trials, navigating regulatory paths, and commercializing the device to support gynecologists in improving preterm birth risk assessment and management.

ScarTec Therapeutics

Grant in 2019
ScarTec Therapeutics develops novel peptide-based technology for scar-free healing.

MyoSwiss

Grant in 2019
MyoSwiss AG, founded in 2017 and based in Zurich, Switzerland, specializes in medical technology aimed at enhancing mobility for individuals with muscle weakness. The company develops innovative products such as the Myofit and Myosuit, which serve as advanced training devices for rehabilitation and physiotherapy. These devices are designed to improve the quality of life for users by providing an additional layer of muscle support, thereby enabling them to regain their mobility and independence. MyoSwiss also offers personalized training plans, intensive activity-based training, and performance tracking to enhance the effectiveness of its solutions, helping individuals with mobility impairments realize their potential for physical activity.

ThermoSiv

Grant in 2019
ThermoSiv Technologies specializes in developing advanced heating solutions, focusing on energy efficiency, safety, and health. The company has created ThermoFabric products that utilize carbon-based conductive materials to provide safe and effective far-infrared therapy. These fabrics emit therapeutic rays within the 8-14 micron spectrum, allowing users to warm themselves efficiently while reducing energy consumption during colder months. ThermoSiv addresses critical needs in heating technology that have often been overlooked, offering innovative solutions that promote both comfort and well-being.

Brainmarc

Grant in 2019
Brainmarc Ltd. is a company based in Yokne'am, Israel, with an additional location in Hoboken, New Jersey, that specializes in developing a digital platform for cognitive remediation. Founded in 2013, the company utilizes its proprietary Brain Engagement Index (BEI) technology to measure brain engagement and mental activity through electroencephalography (EEG) sensors integrated into headsets. Brainmarc's platform offers therapeutic products aimed at addressing cognitive and mental disorders, demonstrating significant effectiveness in treating cognitive impairments. This technology has been validated through numerous patient cases in clinical settings across the United States, Canada, the European Union, and Israel, providing a reliable solution for measuring attention levels during cognitive exercises.

Espansione Group

Grant in 2019
Espansione Group is a medical technology company specializing in the development and distribution of innovative, non-invasive devices for ophthalmology. Their product portfolio includes proprietary photobiomodulation devices, light therapy systems using red, blue, and ultraviolet light, and diagnostic tools for eye screening. These solutions are designed to enhance patient outcomes by leveraging advanced, science-driven therapies, primarily serving the ophthalmology field.

Minnemera

Grant in 2019
Minnemera is a company based in Stockholm, Sweden, that specializes in developing digital cognitive screening tools. Founded in 2017, the company focuses on creating neurocognitive tests that automatically compare individual results with normative data and personal baseline values to identify abnormalities. This innovative approach aims to enhance the assessment of cognitive function and support healthcare professionals in diagnosing and monitoring cognitive health.

MedLumics

Grant in 2019
Medlumics S.L., founded in 2009 and based in Tres Cantos, Spain, specializes in designing and manufacturing catheter-based systems for the treatment of supraventricular tachycardias. The company focuses on developing integrated photonic devices that utilize optical coherence tomography technology, a light-based diagnostic method providing detailed information about tissue structures. Medlumics' radiofrequency cardiac ablation system enhances the treatment process by delivering real-time visual confirmation of catheter contact and stability during tissue ablation. This innovation aims to reduce recurrence rates and technical complexity in procedures, ultimately increasing safety for patients undergoing cardiac interventions.

E-Motion Medical

Grant in 2019
E-Motion Medical Ltd was founded in 2011 by a pioneering multidisciplinary team with extensive experience in medicine, science, management and business. The E-Motion System™ delivers unique patterns of stimulation to the esophagus, thereby generating contractions, which restore natural function to the digestive system and promote motility throughout the gastrointestinal tract. The stimulation is applied to the esophagus using their proprietary E-Motion Tube™, which can also double as a feeding tube, and is easily placed in the same manner.

Capitainer

Grant in 2019
Capitainer AB, based in Stockholm, Sweden, specializes in manufacturing innovative blood collection devices for micro sampling, allowing patients to collect their own volume-defined dried blood spots at home. Founded in 2016, Capitainer's technology offers a more accurate and convenient alternative to traditional blood sampling methods, significantly reducing the need for patients to travel for tests. By facilitating remote blood sample collection that can be sent to laboratories through regular mail, Capitainer enhances the efficiency of healthcare providers and contributes to cost and environmental savings associated with managing conventional blood samples.

CMI NOV

Grant in 2019
CMI NOV is a healthcare company based in Monistrol sur Loire, France, specializing in the design, development, and manufacturing of medical devices for surgical applications. Founded in 2013, the company focuses on various medical fields, including cardiology, visceral surgery, gynecology, urology, and bariatrics. Notably, CMI NOV offers solutions for mitral valve repair, enhancing surgical procedures during open heart surgeries. Through its innovative products, the company aims to improve patient outcomes and support healthcare professionals in delivering high-quality surgical care.

Magentiq Eye

Grant in 2019
Magentiq Eye Ltd. is a medical device company based in Haifa, Israel, established in 2014. It specializes in developing advanced technologies for endoscopic procedures, particularly focusing on automatic polyp detection during colonoscopies. The company's flagship product, the Automatic Polyp Detection System (APDS), leverages deep learning and computer vision to enhance the accuracy of polyp identification, thereby reducing the miss rate during examinations. The APDS is available in two formats: APDS-RT, which operates in real-time by processing video feeds from endoscopic cameras, and APDS-OFL, which analyzes pre-recorded colonoscopy videos. Given the prevalence of colonoscopies—approximately 40 million performed annually—the system aims to improve patient outcomes by increasing detection rates and minimizing the risk of interval cancers. Magentiq Eye's technology not only supports physicians in making more informed decisions during procedures but also has the potential for integration with existing endoscopic equipment or as a service model for clinics and hospitals.

Revamp Medical

Grant in 2019
Revamp Medical, founded in 2016, focuses on addressing the urgent unmet needs of patients suffering from acute heart failure, a condition that leads to over one million annual hospital admissions in the United States and incurs significant healthcare costs. The company has developed the Doraya™ catheter, a patented device designed to regulate vascular hemodynamics in these patients. This innovative solution targets issues such as diuretic resistance by managing preload and reducing central venous pressure, ultimately enhancing the efficacy of diuretics and facilitating progressive decongestion. Revamp Medical is backed by a team of experienced professionals with a strong background in medical technology startups, positioning the company to deliver an easily adoptable treatment option that addresses a critical gap in heart failure care.

Cellex

Grant in 2019
BioCom is a highly innovative Company in the biomedical sector, focused on research, development and manufacture of cutting-edge medical devices, as well as the development of new technologies for surgery, diagnostics and biomedical research.

Advanced Microfluidics

Grant in 2019
Advanced Microfluidics, based in Ecublens, Switzerland, is a machinery manufacturing company that specializes in developing and producing high-end lab equipment components. Their primary focus is on automated liquid handling systems, which are designed to minimize cross-contamination and reduce internal volume, ensuring precise and efficient fluidic performance. The company's products cater to both laboratory and industrial sectors, providing solutions with no dead volumes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.